{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:01:30Z","timestamp":1790096490418,"version":"4.0.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL\/T) groups, the response rates were 17% (7\/42), 7% (1\/15), and 31% (11\/36), respectively. Of the 19 responders, 7 were diffuse large B-cell non-Hodgkin lymphoma (NHL), 7 T-cell NHL, 1 follicular grade 2, and 4 HL. The median response duration for the 19 responders was 7.2 months (mean, 15.8 months; range, 1.8-62), and 5 patients in the HL\/T group are still receiving treatment at 29-64+ months. The grade 3\/4 toxicities observed were fatigue and reversible myelosuppression. Correlative studies suggest that Bim and Bcl-2 should be examined as potential predictors of response in future studies. These results indicate that tipifarnib has activity in lymphoma, particularly in heavily pretreated HL\/T types, with little activity in follicular NHL. In view of its excellent toxicity profile and novel mechanism of action, further studies in combination with other agents appear warranted. This trial is registered at www.clinicaltrials.gov as #NCT00082888.<\/jats:p>","DOI":"10.1182\/blood-2011-02-334904","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T11:30:02Z","timestamp":1309779002000},"page":"4882-4889","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas"],"prefix":"10.1182","volume":"118","author":[{"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N. M.","family":"Micallef","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Porrata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Colgan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Allmer","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Weiner","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Hohl","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kurtin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husheng","family":"Ding","sequence":"additional","affiliation":[{"name":"Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Loegering","sequence":"additional","affiliation":[{"name":"Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Schneider","sequence":"additional","affiliation":[{"name":"Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Peterson","sequence":"additional","affiliation":[{"name":"Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine and"},{"name":"Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111808160102100_B1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"issue":"23","key":"2019111808160102100_B2","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111808160102100_B3","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/cncr.25005","article-title":"The treatment of recurrent\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.","volume":"116","author":"Zent","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"2019111808160102100_B4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808160102100_B5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"issue":"13","key":"2019111808160102100_B6","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111808160102100_B7","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808160102100_B8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111808160102100_B9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/13543781003801076","article-title":"Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.","volume":"19","author":"Epling-Burnette","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"2019111808160102100_B10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/1568026033452050","article-title":"Farnesyl protein transferase inhibitor ZARNESTRA R115777: history of a discovery.","volume":"3","author":"Venet","year":"2003","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"2019111808160102100_B11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2005.04.005","article-title":"Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.","volume":"7","author":"Sebti","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111808160102100_B12","first-page":"131","article-title":"Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.","volume":"61","author":"End","year":"2001","journal-title":"Cancer Res"},{"issue":"5","key":"2019111808160102100_B13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/14737140.4.5.843","article-title":"Role of farnesyltransferase inhibitors in hematologic malignancies.","volume":"4","author":"Santos","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"2019111808160102100_B14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/156652405774641052","article-title":"Targeting the process of farynesylation for therapy of hematologic malignancies.","volume":"5","author":"Karp","year":"2005","journal-title":"Curr Mol Med"},{"key":"2019111808160102100_B15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.seminoncol.2003.12.012","article-title":"Farnesyltransferase inhibitors.","volume":"31","author":"Sebti","year":"2004","journal-title":"Semin Oncol"},{"issue":"11","key":"2019111808160102100_B16","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111808160102100_B17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/erc.0.0110191","article-title":"Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?","volume":"11","author":"O'Regan","year":"2004","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2019111808160102100_B18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/MCB.20.1.139-148.2000","article-title":"The phosphoinositide 3-OH kinase\/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.","volume":"20","author":"Jiang","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"16","key":"2019111808160102100_B19","first-page":"4796","article-title":"Implication of protein kinase B\/Akt and Bcl-2\/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.","volume":"63","author":"Chun","year":"2003","journal-title":"Cancer Res"},{"issue":"35","key":"2019111808160102100_B20","doi-asserted-by":"crossref","first-page":"32493","DOI":"10.1074\/jbc.C300226200","article-title":"Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.","volume":"278","author":"Castro","year":"2003","journal-title":"J Biol Chem"},{"issue":"16","key":"2019111808160102100_B21","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1101\/gad.1690808","article-title":"Tumorigenic activity and therapeutic inhibition of Rheb GTPase.","volume":"22","author":"Mavrakis","year":"2008","journal-title":"Genes Dev"},{"key":"2019111808160102100_B22","article-title":"Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim upregulation [published online ahead of print June 14, 2011].","author":"Ding","journal-title":"Blood"},{"issue":"22","key":"2019111808160102100_B23","first-page":"5302","article-title":"A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.","volume":"55","author":"Sepp-Lorenzino","year":"1995","journal-title":"Cancer Res"},{"issue":"19","key":"2019111808160102100_B24","first-page":"4919","article-title":"Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.","volume":"59","author":"Sun","year":"1999","journal-title":"Cancer Res"},{"issue":"57","key":"2019111808160102100_B25","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1038\/sj.onc.1208122","article-title":"ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL).","volume":"23","author":"Epling-Burnette","year":"2004","journal-title":"Oncogene"},{"issue":"4","key":"2019111808160102100_B26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111808160102100_B27","first-page":"2318","article-title":"Comparison of potential markers of farnesyltransferase inhibition.","volume":"6","author":"Adjei","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2019111808160102100_B28","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2008-08-172726","article-title":"Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.","volume":"113","author":"Karp","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111808160102100_B29","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2007-09-112730","article-title":"A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.","volume":"111","author":"Raponi","year":"2008","journal-title":"Blood"},{"key":"2019111808160102100_B30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1476-4598-7-39","article-title":"Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.","volume":"7","author":"Field","year":"2008","journal-title":"Mol Cancer"},{"issue":"23","key":"2019111808160102100_B31","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1200\/JCO.2004.03.200","article-title":"Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.","volume":"22","author":"Zimmerman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111808160102100_B32","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/sj.leu.2404816","article-title":"A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.","volume":"21","author":"Mesa","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"2019111808160102100_B33","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2019111808160102100_B34","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1182\/blood-2002-11-3359","article-title":"Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.","volume":"102","author":"Kurzrock","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2019111808160102100_B35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2004.08.082","article-title":"Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.","volume":"22","author":"Kurzrock","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808160102100_B36","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-007-0543-3","article-title":"Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.","volume":"61","author":"Rolland","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2019111808160102100_B37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00280-009-1185-4","article-title":"Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed\/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.","volume":"65","author":"Rolland","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2019111808160102100_B38","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.","volume":"109","author":"Lancet","year":"2007","journal-title":"Blood"},{"issue":"19","key":"2019111808160102100_B39","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1158\/0008-5472.CAN-09-1606","article-title":"Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.","volume":"69","author":"Dai","year":"2009","journal-title":"Cancer Res"},{"issue":"8","key":"2019111808160102100_B40","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1158\/1078-0432.CCR-08-2658","article-title":"Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.","volume":"15","author":"Sparano","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111808160102100_B41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/leu.2008.341","article-title":"A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.","volume":"23","author":"Brandwein","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2019111808160102100_B42","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/cncr.25575","article-title":"A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4882\/1463724\/zh804411004882.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4882\/1463724\/zh804411004882.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:37:18Z","timestamp":1712576238000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/18\/4882\/29345\/Multiinstitutional-phase-2-study-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,3]]},"references-count":42,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,11,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-334904","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,3]]}}}